Melatonin plays a protective role in quinolinic acid-induced neurotoxicity in the rat hippocampus

Journal of Chemical Neuroanatomy

Volumn 14, Issue 3-4, 1998, Pages 151-156

  Southgate, G S ^a   Daya, S ^a   Potgieter, B ^a  

^a RHODES UNIVERSITY   (South Africa)

Author keywords

Binding studies; Neurodegeneration; Neuroprotection

Indexed keywords

GLUTAMATE RECEPTOR; MELATONIN; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; HIPPOCAMPUS; MALE; MICROSCOPY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY;

ANIMALS; ANTIOXIDANTS; DRUG INTERACTIONS; HIPPOCAMPUS; MALE; MELATONIN; NEURONS; QUINOLINIC ACID; RATS; RATS, WISTAR; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0032104709     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-0618(98)00026-X     Document Type: Conference Paper

References (25)

1. ña-Castroviejo et al., 1993
2. Acuña-Castroviejo D., Pablos M.I., Menendez-Pelaez A., Reiter R.J. Melatonin receptors in purified cell nuclei of liver. Res. Commun. Chem. Pathol. Pharmacol. 82:1993;253-256.
3. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's Disease by quinolinic acid. Nature. 321:1986;169-171.
4. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
5. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's Disease: Evidence supporting it. Ann. Neurol. 32:1992;804-812.
6. Giusti P., Gusella M., Lipartiti M., Milani D., Zhu W., Vicini S., Manev H. Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-methyl-D-aspartate excitotoxicity. Exp. Neurol. 131:1995;39-46.
7. Glowinski J., Iversen L.L. Regional studies of catecholamines in the rat brain-I. J. Neurochem. 13:1966;655-669.
8. önig and Klippel, 1963
9. König, J.F.R., Klippel, R.A., 1963. The Rat Brain. Williams and Wilkins, Baltimore, MD.
10. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin Phenol Reagent. J. Biol. Chem. 193:1951;265-275.
11. Morgan D.J., Williams L.M. Central melatonin receptors: Implication for a mode of action. Experientia. 45:1989;955-965.
12. Moroni F., Lombard G., Moneti G., Aldinio C. The excitotoxin quinolinic acid is present in the brain of several mammals and its cortical content increases during the aging process. Neurosci. Lett. 47:1984;51-55.
13. Popoli P., Pèzzola A., Domenici M.R., Sagratella S., Diana G., Caporali M.G., Bronzetti E., Vega J., Scotti de Carolis A. Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington's Disease in rats. Brain Res. Bull. 35:1994;329-335.
14. Reiter R.J., Melchiorri D., Sewerynek E., Poeggeler B., Barlow-Walden L., Chuang J., Ortiz G.G., Acuña-Castroviejo D. A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res. 18:1995;1-11.
15. Reiter R.J. The melatonin message: Duration versus coincidence hypotheses. Life Sci. 40:1987;2119-2131.
16. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor. Trends Neurosci. 10:1987;299-302.
17. öhler, 1983
18. Schwarcz R., Köhler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 38:1983;85-90.
19. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 219:1983;316-318.
20. Shaw P.J. Excitotoxicity and motor neurone disease: a review of the evidence. J. Neurol. Sci. 124:1994;6-13.
21. Stone T.W., Perkins M.N. Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72:1981;411-412.
22. Tan D.X., Chen L.D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocr. J. 1:1993;57-60.
23. Tan D.-F., Reiter R.J., Chen L., Poeggeler B., Manchester L.C., Barlow-Walden L.R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis. 15:1994;215-218.
24. Wolfensberger M., Amsler U., Cuénod M., Foster A.C., Whetsell W.O. Jr., Schwarcz R. Identification of quinolinic acid in rat and human brain tissue. Neurosci. Lett. 41:1983;247-252.
25. 3H](+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine (MK-801) binding in brain synaptic membranes treated with Triton X-100. J. Pharmacol. Exp. Ther. 256:1991;1161-1172.